$JNJ Headlines Why you should favor large-cap stocks

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2014 at 12:40 PM

$JNJ Headlines

Why you should favor large-cap stocks for the next six weeks 8:53 p.m. Nov. 16, 2014 - Mark Hulbert
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Republican victory will boost these 21 stocks 7:45 a.m. Nov. 5, 2014 - Michael Brush
Ebola play Halyard Health stock gains are modest 1:02 p.m. Nov. 3, 2014 - Russ Britt
Ebola-nation travelers to U.S. to be watched 21 days 3:04 p.m. Oct. 22, 2014 - Russ Britt
Johnson & Johnson to begin testing Ebola vaccine in January 9:14 a.m. Oct. 22, 2014 - Jonathan D. Rockoff
A possible new Ebola vaccine from Johnson&Johnson 4:32 a.m. Oct. 22, 2014 - MarketWatch
Fighting Ebola though investing: one firm’s approach 6:42 p.m. Oct. 21, 2014 - Wallace Witkowski
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
Updates, advisories and surprises 5:31 p.m. Oct. 14, 2014 - MarketWatch
Delta, Citigroup gain; J.P. Morgan, Wells Fargo slide following results 10:58 a.m. Oct. 14, 2014 - Sue Chang
Newscast: Google launches same-day delivery 9:58 a.m. Oct. 14, 2014 - MarketWatch
All the reasons to sell this market are enough to draw a guy in 9:23 a.m. Oct. 14, 2014 - Shawn Langlois
J&J's earnings jump on higher drug sales 8:12 a.m. Oct. 14, 2014 - MarketWatch.com
Johnson & Johnson shares gain after profit beat, raised outlook 7:59 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson shares up 1% premarket after Q3 results 7:50 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson ups 2014 EPS outlook to $5.92-$5.97 from $5.85-$5.92 7:50 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson Q3 net EPS $1.66 vs. $1.04 a year ago 7:49 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson Q3 sales of $18.5 bln vs. FactSet consensus $18.44 bln 7:48 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson Q3 sales up 5.1% from last year to $18.5 bln 7:47 a.m. Oct. 14, 2014 - Tomi Kilgore

DexCom Still A Favorite Diabetes Stock 11:15 a.m. Today - Seeking Alpha
Guru Ken Fisher's Top Five Quarterly Stocks 10:17 p.m. Nov. 16, 2014 - GuruFocus.com
Value Investors' Most Loved Stocks In Q3 2014 9:09 a.m. Nov. 16, 2014 - Seeking Alpha
Retirement Strategy: Annuities Vs. Dividend Growth Investing For A Lifetime Income 12:01 a.m. Nov. 15, 2014 - Seeking Alpha
Geron Collaborates with J&J for Imetelstat - Analyst Blog 6:00 p.m. Nov. 14, 2014 - Zacks.com
Significant Changes In Buffett and Berkshire Hathaway Holdings 4:18 p.m. Nov. 14, 2014 - 247WallSt.com
Geron's Short Squeeze Is Here 3:40 p.m. Nov. 14, 2014 - Seeking Alpha
Mallinckrodt Shares Down on Setback for Generic Concerta - Analyst Blog 3:39 p.m. Nov. 14, 2014 - Zacks.com
Stock Market Today: Stocks Mixed as Retail Sales Climb, House OKs Keystone Pipeline 3:36 p.m. Nov. 14, 2014 - TheStreet.com
What Licensing Imetelstat Will Mean for Geron 10:45 a.m. Nov. 14, 2014 - 247WallSt.com
Setting Up A Portfolio That Millennials Can Relate To 10:05 a.m. Nov. 14, 2014 - Seeking Alpha
The Post AASLD Annual Meeting Hepatitis C Landscape 6:15 a.m. Nov. 14, 2014 - Seeking Alpha
Geron wins deal to develop blood disorder drug, could get $935M 5:55 p.m. Nov. 13, 2014 - Seeking Alpha
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog 5:10 p.m. Nov. 13, 2014 - Zacks.com
Geron Licenses Experimental Myelofibrosis Drug to Johnson & Johnson 4:34 p.m. Nov. 13, 2014 - TheStreet.com
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak 4:24 p.m. Nov. 13, 2014 - Seeking Alpha
Total Return And Dividend Growth Investing 3:50 p.m. Nov. 13, 2014 - Seeking Alpha
Mallinckrodt Says FDA Reclassified ADHD Generic Drug 1:21 p.m. Nov. 13, 2014 - The Wall Street Journal Interactive Edition
Does The End Of QE Portend A New Beginning For Income Investors? 12:48 p.m. Nov. 13, 2014 - Seeking Alpha
Mallinckrodt ADHD Drug Hits FDA Trouble; Stock Drops 10:09 a.m. Nov. 13, 2014 - Investors Business Daily

Nicholas Valeriani Appointed To Edwards Lifesciences' Board Of Directors 9:00 a.m. Nov. 14, 2014 - PR Newswire - PRF
Amcor Rigid Plastics Renews National Sponsorshipof America Recycles Day 2014 7:29 p.m. Nov. 11, 2014 - BusinessWire - BZX
La Lumiere Closes $20 Million Series B Financing 8:02 a.m. Nov. 11, 2014 - PR Newswire - PRF
CORRECTING and REPLACING Biosense Webster Teams Up with StopAfib.org to Challenge Americans to Get SMART About AfibSM 7:40 p.m. Nov. 10, 2014 - BusinessWire - BZX
VYCOR: "On the Cusp of the Next Big Healthcare Trend" 9:23 a.m. Nov. 10, 2014 - ACCESSWIRE
HackerAgency Names New Director of Strategic Planning; Adds Senior Client Leadership 8:35 a.m. Nov. 10, 2014 - PR Newswire - PRF
Biosense Webster Teams Up with StopAfib.org to Challenge Americans to Get SMART About AfibSM 8:03 a.m. Nov. 10, 2014 - BusinessWire - BZX
New President and New Offices Signal New Era for New Jersey-based BNO 6:36 p.m. Nov. 7, 2014 - PR Newswire - PRF
Johnson & Johnson Announces Completion Of Alios BioPharma Acquisition 4:05 p.m. Nov. 7, 2014 - PR Newswire - PRF
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA 8:50 a.m. Nov. 7, 2014 - PR Newswire - PRF
Alios BioPharma to Present Preclinical Data on Its Anti-HCV Nucleotides AL-335 and AL-516 at the 2014 American Association for the Study of Liver Diseases Annual Meeting 4:20 p.m. Nov. 6, 2014 - Marketwired
DECN's Subsidiary Initiates First in Industry Social Media Marketing Campaign for Genstrip50 9:26 a.m. Nov. 5, 2014 - ACCESSWIRE
Baron and Budd Investigating Potential Xarelto Lawsuits 4:03 p.m. Nov. 4, 2014 - BusinessWire - BZX
Legal-Bay Lawsuit Settlement Funding Updates News on All Major Hip Litigations 5:00 a.m. Nov. 4, 2014 - PR Newswire - PRF
Coronary Stents Market (Bare Metal Stents, Drug Eluting Stents and Bio-absorbable Stents) - Global Industry Analysis, Size, Share, Pipeline Overview, Growth, Trends and Forecast, 2013 - 2019 8:00 p.m. Oct. 30, 2014 - PR Newswire - PRF
In 2023, Medivation/Astellas Pharma's Xtandi Will Be the Top-Selling Agent in the Prostate Cancer Market Across the United States, Europe, and Japan 1:00 p.m. Oct. 30, 2014 - PR Newswire - PRF
Financial Results, Program Expansion, Product Launch, and Share Dealings - Research Reports on Merck, Johnson & Johnson, Amgen, Medtronic and Shire 9:15 a.m. Oct. 30, 2014 - PR Newswire - PRF
Johnson & Johnson Diabetes Solutions Companies Join The Joslin Institute for Technology Translation (JITT) As Founding Members 9:00 a.m. Oct. 30, 2014 - BusinessWire - BZX
Capital Increase in Bavarian Nordic A/S as a Result of Completion of a Direct Placement to Johnson & Johnson Development Corporation 5:15 a.m. Oct. 29, 2014 - Thomson Reuters ONE
Johnson & Johnson Innovation Launches Asia Pacific Innovation Center and Announces New Alliances 4:00 p.m. Oct. 28, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Steady Income Boosts FHLBank Boston's Growth Q3 2026

The Federal Home Loan Bank of Boston dropped their third-quarter results for 2026 like a hot smokestack, and let me tell you, it's a mixed bag of cautious optimism and steady progression. It's essentially proof that slow and steady might just win the race—or at least keep you in the running. Stable and Steady Headway Taking a peek under the hood, FHLBank Boston made a...

Salus Scientific Pioneers Safety at TCT 2026

Revolutionizing Occupational Safety in Healthcare Radiation exposure in the medical field: the dull, ominous toll it takes on healthcare professionals, often cloaked in acceptance as a mere occupational hazard. But here's Salus Scientific crashing into the party at TCT 2026 like a seasoned rockstar, demanding we stop accepting the dangers of fluoroscopy-guided procedures...

CobbleStone Partners with Hatch: Impact on CLM Success

Seeing CobbleStone Software team up with Hatch Advisory feels like stumbling across an old pal leading a promising venture down the innovation road. This partnership isn't just another handshaking ceremony—it's a real shift for the tech-adoption space, especially in the contract lifecycle management (CLM) domain, where CobbleStone already has quite the footprint....

Coastal’s Class Action: Credit Missteps Lead to 43% Drop

Coastal's Big Misstep: A Costly Setback Hey, when a stock drops like a rock on negative news, it's a sign for those on the sidelines to take note. Coastal Financial Corporation, known by its ticker NASDAQ: CCB, felt the hard slap of market reality when a single-day nosedive shaved off a hefty 43% of its stock value. It's all thanks to a whopper of a securities class...

BOB Raises $5.5M for AI Banking Platform Revolution

Cracking the Code of Small Business Finance BOB, a Miami hotshot aiming to be more than just another fintech flash in the pan, has wrangled a sweet $5.5 million in seed capital. They're shaking hands with big names like Peter Thiel and the mastermind behind Plaid, Zak Perret, through Mischief Ventures. The plan? To build an AI-powered finance savior for small businesses...

Beyond The Bounce Expands with Pro Pickleball Star

Pickleball's Power Play: The Media Move Out of the blue, the world of niche sports finds its hub. Beyond The Bounce steps up to the plate by roping in pickleball’s own Zane Navratil. The hype’s not in the spin here—this is serious business. The company plans to push the boundaries of the sport into mainstream media, or at least give it a decent shot. Zane Navratil:...

VoxNexus Debuts On-Device AI: A Game-Changer for Languages

VoxNexus Changes the Game with VoxEdge Here's the rub with tech: it often feels like it's only for the folks who already have a leg up. VoxNexus just flipped the script with its new product, VoxEdge, an on-device voice stack that's making waves by breaking language barriers in the ever-evolving AI world. This move might just shift the landscape of voice artificial...

Paolo Moretti: New CEO Steering RINA's Dynamic Course

Leadership Shift in the Heart of RINA Today's news is a hefty dose of strategic sea change over at RINA S.p.A., where Paolo Moretti's been handed the reins as the new Group Chief Executive Officer. Now, if you haven't been following, RINA's been riding a serious wave—revenues have more than doubled in a neat five-year streak, claiming over a billion euros. So, what we...

Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...